| Kaiser Foundation Hospital - Riverside Hospice 10917 Magnolia Avenue, Riverside, CA, 92505 | |
| (951) 358-2600 |
News Archive
The World Health Organization has issued new rules to limit the international spread of epidemics and other public health emergencies.
BioTrends Research Group, Inc. released Wave 1 of its LaunchTrends(TM): Stelara report, the first in a multi-phase syndicated market research project tracking the launch of Centocor Ortho-Biotech's Stelara, from product launch through the first six months of availability. Each wave of the report provides quantitative information from 75 unique Dermatologists and qualitative information from a subset of 20.
Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) has granted full approval for Sprycel (dasatinib) for the treatment of adults in all phases of chronic myeloid leukemia (CML) (chronic, accelerated, or myeloid or lymphoid blast phase) with resistance or intolerance to prior therapy including Gleevec (imatinib mesylate).
The majority of women who undergo contralateral prophylactic mastectomy do so out of fear that their breast cancer will recur, rather than because they have a clinically high risk for recurrence, indicate US study results.
Texas Children's Hospital is the first hospital in the world to use real-time MRI-guided thermal imaging and laser technology to destroy lesions in the brain that cause epilepsy and uncontrollable seizures.
› Verified 4 days ago
| Name | Kaiser Foundation Hospital - Riverside Hospice |
|---|---|
| Location | 10917 Magnolia Avenue, Riverside, California |
| Hospice ID | 551743 |
| Category | Freestanding Hospice |
| Ownership Type | Other |
| Profit Type | OTHER |
| Accreditation Provider | The Joint Commission (TJC) |
| SSA county code | 430 |
News Archive
The World Health Organization has issued new rules to limit the international spread of epidemics and other public health emergencies.
BioTrends Research Group, Inc. released Wave 1 of its LaunchTrends(TM): Stelara report, the first in a multi-phase syndicated market research project tracking the launch of Centocor Ortho-Biotech's Stelara, from product launch through the first six months of availability. Each wave of the report provides quantitative information from 75 unique Dermatologists and qualitative information from a subset of 20.
Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) has granted full approval for Sprycel (dasatinib) for the treatment of adults in all phases of chronic myeloid leukemia (CML) (chronic, accelerated, or myeloid or lymphoid blast phase) with resistance or intolerance to prior therapy including Gleevec (imatinib mesylate).
The majority of women who undergo contralateral prophylactic mastectomy do so out of fear that their breast cancer will recur, rather than because they have a clinically high risk for recurrence, indicate US study results.
Texas Children's Hospital is the first hospital in the world to use real-time MRI-guided thermal imaging and laser technology to destroy lesions in the brain that cause epilepsy and uncontrollable seizures.
› Verified 4 days ago
| NPI Number | 1720229602 |
| Organization Name | Kaiser Foundation Hospitals |
| Address | 10917 Magnolia Ave Riverside, California, 92505 |
| Phone Number | (951)358-2600 |
News Archive
The World Health Organization has issued new rules to limit the international spread of epidemics and other public health emergencies.
BioTrends Research Group, Inc. released Wave 1 of its LaunchTrends(TM): Stelara report, the first in a multi-phase syndicated market research project tracking the launch of Centocor Ortho-Biotech's Stelara, from product launch through the first six months of availability. Each wave of the report provides quantitative information from 75 unique Dermatologists and qualitative information from a subset of 20.
Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) has granted full approval for Sprycel (dasatinib) for the treatment of adults in all phases of chronic myeloid leukemia (CML) (chronic, accelerated, or myeloid or lymphoid blast phase) with resistance or intolerance to prior therapy including Gleevec (imatinib mesylate).
The majority of women who undergo contralateral prophylactic mastectomy do so out of fear that their breast cancer will recur, rather than because they have a clinically high risk for recurrence, indicate US study results.
Texas Children's Hospital is the first hospital in the world to use real-time MRI-guided thermal imaging and laser technology to destroy lesions in the brain that cause epilepsy and uncontrollable seizures.
› Verified 4 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 100.0 | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 100.0 | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | 95.8 | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | 92.7 | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | 97.9 | 97.3 |
| Patients who got timely treatment for shortness of breath | 96.3 | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | 97.1 | 93.3 |
News Archive
The World Health Organization has issued new rules to limit the international spread of epidemics and other public health emergencies.
BioTrends Research Group, Inc. released Wave 1 of its LaunchTrends(TM): Stelara report, the first in a multi-phase syndicated market research project tracking the launch of Centocor Ortho-Biotech's Stelara, from product launch through the first six months of availability. Each wave of the report provides quantitative information from 75 unique Dermatologists and qualitative information from a subset of 20.
Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) has granted full approval for Sprycel (dasatinib) for the treatment of adults in all phases of chronic myeloid leukemia (CML) (chronic, accelerated, or myeloid or lymphoid blast phase) with resistance or intolerance to prior therapy including Gleevec (imatinib mesylate).
The majority of women who undergo contralateral prophylactic mastectomy do so out of fear that their breast cancer will recur, rather than because they have a clinically high risk for recurrence, indicate US study results.
Texas Children's Hospital is the first hospital in the world to use real-time MRI-guided thermal imaging and laser technology to destroy lesions in the brain that cause epilepsy and uncontrollable seizures.
› Verified 4 days ago
| Home Health Aides | 2 |
| Counselors | 1 |
| Homemakers | 2 |
| Medical Social Workers | 2 |
| Physicians | 2 |
| Registered Nurses | 5 |
| Other Personnel | 2 |
| Total Employees | 16 |
|---|
News Archive
The World Health Organization has issued new rules to limit the international spread of epidemics and other public health emergencies.
BioTrends Research Group, Inc. released Wave 1 of its LaunchTrends(TM): Stelara report, the first in a multi-phase syndicated market research project tracking the launch of Centocor Ortho-Biotech's Stelara, from product launch through the first six months of availability. Each wave of the report provides quantitative information from 75 unique Dermatologists and qualitative information from a subset of 20.
Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) has granted full approval for Sprycel (dasatinib) for the treatment of adults in all phases of chronic myeloid leukemia (CML) (chronic, accelerated, or myeloid or lymphoid blast phase) with resistance or intolerance to prior therapy including Gleevec (imatinib mesylate).
The majority of women who undergo contralateral prophylactic mastectomy do so out of fear that their breast cancer will recur, rather than because they have a clinically high risk for recurrence, indicate US study results.
Texas Children's Hospital is the first hospital in the world to use real-time MRI-guided thermal imaging and laser technology to destroy lesions in the brain that cause epilepsy and uncontrollable seizures.
› Verified 4 days ago
| Home Health Aides | 4 |
| Total Volunteers | 4 |
|---|
News Archive
The World Health Organization has issued new rules to limit the international spread of epidemics and other public health emergencies.
BioTrends Research Group, Inc. released Wave 1 of its LaunchTrends(TM): Stelara report, the first in a multi-phase syndicated market research project tracking the launch of Centocor Ortho-Biotech's Stelara, from product launch through the first six months of availability. Each wave of the report provides quantitative information from 75 unique Dermatologists and qualitative information from a subset of 20.
Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) has granted full approval for Sprycel (dasatinib) for the treatment of adults in all phases of chronic myeloid leukemia (CML) (chronic, accelerated, or myeloid or lymphoid blast phase) with resistance or intolerance to prior therapy including Gleevec (imatinib mesylate).
The majority of women who undergo contralateral prophylactic mastectomy do so out of fear that their breast cancer will recur, rather than because they have a clinically high risk for recurrence, indicate US study results.
Texas Children's Hospital is the first hospital in the world to use real-time MRI-guided thermal imaging and laser technology to destroy lesions in the brain that cause epilepsy and uncontrollable seizures.
› Verified 4 days ago
| Vitas Healthcare Corporation Of California Location: 7888 Mission Grove Parkway S, Suite 200, Riverside, California, 92508 Phone: (951) 358-2600 |
| Ascend Hospice Location: 7344 Magnolia Ave, Ste 245, Riverside, California, 92504 Phone: (951) 358-2600 |
| Companion Hospice, Llc Location: 4199 Flat Rock Drive, Suite 200, Riverside, California, 92505 Phone: (951) 358-2600 |
| Inland Valley Hospice Location: 3770 Myers Street, Riverside, California, 92503 Phone: (951) 358-2600 |